Background: is highly pleiotropic, with the e4 allele the strongest genetic risk factor for late‐onset Alzheimer’s disease (AD) and associated with other cardiometabolic traits. The *e4 allele demonstrates ancestry‐specific differences in the risk for AD. Here, we investigated whether similar ancestry‐specific effects are observed across other AD endophenotypes and modifiable risk factors for AD.

Method: Participants were 2505 non‐Hispanic Whites, Hispanics, and African Americans with genetic data from the Health and Aging Brain Study ‐ Health Disparities cohort (Table 1). Genetic ancestry was determined through principal component analysis, by projecting participants onto the 1000 Genomes reference panel. Global ancestry proportions were estimated using ADMIXTURE. The association of *e4+ and *e2+ alleles with cognitive performance, plasma biomarkers, neuroimaging, and clinical comorbidities was investigated using regression models stratified by European (EUR), Amerindian (AMR), and African (AFR) ancestry. Covariates included age, gender, education; and intracranial volume for neuroimaging endophenotypes. Ancestry‐specific effects were determined by evaluating the equality in regression coefficients from the ancestry‐stratified models.

Result: Genetic ancestry assignments were highly concordant with self‐reported race: 1071 EUR, 1003 AMR, and 431 AFR participants (Table 1). *e4 was associated with lower BMI, poorer cognitive performance, increased risk of cognitive impairment and dyslipidemia, reduced cortical thickness and hippocampal volume, and plasma biomarkers levels ‐ higher pTau, lower Ab, and Ab/Ab ratios (Figure 1). *e2 was associated with reduced dyslipidemia risk (Figure 2). Notably, ancestry‐specific effects were observed, with *e4 associated with lower Ab/Ab in EUR compared to AMR. Additionally, *e2 shows ancestry‐specific effects for Ab/Ab, pTau and Ab. In particular, AFR have a lower Ab/Ab compared to both EUR and AMR. EUR have lower levels of pTau compared to both AFR and AMR. AFR have higher Ab compared to EUR and AMR.

Conclusion: Our findings demonstrate that the impact of on AD endophenotypes varies across ancestries, notably with amyloid and tau plasma biomarkers, and dyslipidemia. This underscores the critical need to consider genetic ancestry in assessing the effect of on AD endophenotypes.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.095645DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712325PMC

Publication Analysis

Top Keywords

ancestry‐specific effects
20
genetic ancestry
12
plasma biomarkers
12
lower ab/ab
12
endophenotypes modifiable
8
modifiable risk
8
risk factors
8
effects observed
8
cognitive performance
8
*e4 associated
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!